Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma
Open Access
- 6 September 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 13 (12), 1331-1338
- https://doi.org/10.1093/neuonc/nor130
Abstract
This open-label, single-arm, phase II study combined enzastaurin with temozolomide plus radiation therapy (RT) to treat glioblastoma multiforme (GBM) and gliosarcoma. Adults with newly diagnosed disease and Karnofsky performance status (KPS) ≥ 60 were enrolled. Treatment was started within 5 weeks after surgical diagnosis. RT consisted of 60 Gy over 6 weeks. Temozolomide was given at 75 mg/m2 daily during RT and then adjuvantly at 200 mg/m2 daily for 5 days, followed by a 23-day break. Enzastaurin was given once daily during RT and in the adjuvant period at 250 mg/day. Cycles were 28 days. The primary end point was overall survival (OS). Progression-free survival (PFS), toxicity, and correlations between efficacy and molecular markers analyzed from tumor tissue samples were also evaluated. A prospectively planned analysis compared OS and PFS of the current trial with outcomes from 3 historical phase II trials that combined novel agents with temozolomide plus RT in patients with GBM or gliosarcoma. Sixty-six patients were enrolled. The treatment regimen was well tolerated. OS (median, 74 weeks) and PFS (median, 36 weeks) results from the current trial were comparable to those from a prior phase II study using erlotininb and were significantly better than those from 2 other previous studies that used thalidomide or cis-retinoic acid, all in combination with temozolomide plus RT. A positive correlation between O-6-methylguanine-DNA methyltransferase promoter methylation and OS was observed. Adjusting for age and KPS, no other biomarker was associated with survival outcome. Correlation of relevant biomarkers with OS may be useful in future trials.Keywords
This publication has 30 references indexed in Scilit:
- Survival of Patients with Newly Diagnosed Glioblastoma Treated with Radiation and Temozolomide in Research Studies in the United StatesClinical Cancer Research, 2010
- Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I studyNeuro-Oncology, 2010
- A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomasNeuro-Oncology, 2010
- Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or GliosarcomaJournal of Clinical Oncology, 2009
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C β-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced CancerClinical Cancer Research, 2007
- Synergistic antiglioma activity of radiotherapy and enzastaurinAnnals of Neurology, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Protein Kinase C βII Regulates Akt Phosphorylation on Ser-473 in a Cell Type- and Stimulus-specific FashionJournal of Biological Chemistry, 2004
- PKC-η mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathwaysOncogene, 2004
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958